Teprotumumab Efficacy in Retreatment and Longer-Term Thyroid Eye Disease: OPTIC-X Study Results

Teprotumumab, an insulin-like growth factor I receptor inhibitory antibody, improves proptosis, diplopia, inflammatory signs/symptoms, and quality of life in thyroid eye disease (TED) patients.1,2 In the phase 3, randomized, placebo-controlled trial (OPTIC), 83% receiving teprotumumab were responders (≥2 mm proptosis reduction) after 24 weeks (vs. 10% placebo).2 Extension of this trial (OPTIC-X) examined benefit of retreatment (additional 24-week treatment) in those who had disease exacerbation (flare) or were placebo/teprotumumab non-responders, and whether longer disease duration impacts treatment response.